Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice

Bibliography

• Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention pf vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-69
   PubMed Web of Science ®Google Scholar
• Dalen JE. Aspirin for the primary prevention of stroke and myocardial infarction: ineffective or wrong dose? Am J Med 2010;123:101-2
   PubMed Web of Science ®Google Scholar
• Cohen M. Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care. Mayo Clin Proc 2009;84:149-60
   PubMed Web of Science ®Google Scholar
• Lanas A. Nonsteroidal anti-inflammatory drugs and cyclooxygenase inhibition in the gastrointestinal tract: a trip from peptic ulcer to colon cancer. Am J Med Sci 2009;338:96-106
   PubMed Web of Science ®Google Scholar
• Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999;117:17-25
   PubMed Web of Science ®Google Scholar
• Kawai T, Yamagishi T, Goto S. Circadian variations of gastrointestinal mucosal damage detected with transnasal endoscopy in apparently healthy subjects treated with low-dose aspirin (ASA) for a short period. J Atheroscler Thromb 2009;16:155-63
   PubMed Web of Science ®Google Scholar
• Yeomans ND, Lanas AI, Talley NJ, Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005;22:795-801
   PubMed Web of Science ®Google Scholar
• Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000;321:1183-7
   PubMed Web of Science ®Google Scholar
• Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002;16:1945-53
   PubMed Web of Science ®Google Scholar
• Lanas A, Perez-Aisa MA, Feu F, A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005;100:1685-93
   PubMed Web of Science ®Google Scholar
• Lanas A, Garcia-Rodriguez LA, Polo-Tomas M, Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009;104:1633-41
   PubMed Web of Science ®Google Scholar
• Arroyo M, Lanas A. NSAIDs-induced gastrointestinal damage. Review. Minerva Gastroenterol Dietol 2006;52:249-59
   PubMedGoogle Scholar
• Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? Am J Med 2006;119:719-27
   PubMed Web of Science ®Google Scholar
• Mort JR, Aparasu RR, Baer RK. Interaction between selective serotonin reuptake inhibitors and nonsteroidal antiinflammatory drugs: review of the literature. Pharmacotherapy 2006;26:1307-13
   PubMed Web of Science ®Google Scholar
• Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 2007;23:163-73
   PubMed Web of Science ®Google Scholar
• Hernandez-Diaz S, Garcia-Rodriguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med 2006;4:22
   PubMed Web of Science ®Google Scholar
• Chan FK, Chung SC, Suen BY, Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-73
   PubMed Web of Science ®Google Scholar
• Lai KC, Lam SK, Chu KM, Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002;346:2033-8
   PubMed Web of Science ®Google Scholar
• Brzozowski T, Konturek PC, Sliwowski Z, Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals. J Physiol Pharmacol 2006;57(Suppl 3):67-79
   PubMedGoogle Scholar
• Shiotani A, Sakakibara T, Yamanaka Y, The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy. J Gastroenterol 2009;44:717-25
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39
   PubMed Web of Science ®Google Scholar
• Lanas A, Garcia-Rodriguez LA, Arroyo MT, Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006;55:1731-8
   PubMed Web of Science ®Google Scholar
• Yeomans N, Lanas A, Labenz J, Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008;103:2465-73
   PubMed Web of Science ®Google Scholar
• Ng FH, Wong SY, Lam KF, Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastronterology 2010;138:82-8
   PubMed Web of Science ®Google Scholar
• Lanas A, Bajador E, Serrano P, Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000;343:834-39
   PubMed Web of Science ®Google Scholar
• Lanas A, Garcia-Rodriguez LA, Arroyo MT, Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007;102:507-15
   PubMed Web of Science ®Google Scholar
• Chan FK, Ching JY, Hung LC, Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005;352:238-44
   PubMed Web of Science ®Google Scholar
• Antman EM, Anbe DT, Armstrong PW, ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction – executive summary. J Am Coll Cardiol 2004;44:671-19
   PubMedGoogle Scholar
• Braunwald E, Antman EM, Beasley JW, ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction – 2002: summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2002;106:1893-900
   PubMed Web of Science ®Google Scholar
• Task Force Members. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the task force for the diagnosis and treatment of non-st-segment elevation acute coronary syndromes of the European Society of Cardiology. Eur Heart J 2007;28:1598-660
   PubMed Web of Science ®Google Scholar
• Task Force Members. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 2008;29:2909-45
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Mehta SR, Anand SS, Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006;114:774-82
   PubMed Web of Science ®Google Scholar
• Abbas AE, Brodie B, Dixon S, Incidence and prognostic impact of gastrointestinal bleeding after percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2005;96:173-6
   PubMed Web of Science ®Google Scholar
• Aronow HD, Steinhubl SR, Brennan DM, ; CREDO Investigators. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2009;157:369-74
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Scheiman J, Abraham NS, ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008;52:1502-17
   PubMed Web of Science ®Google Scholar
• Gilard M, Arnaud B, Cornily JC, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-60
   PubMed Web of Science ®Google Scholar
• Ho PM, Maddox TM, Wang L, Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). Available from: http://www.fda.gov/Drugs/DrugSafety. [Last accessed 26 March 2010]
   Google Scholar
• EMEA. Public statement on possible interaction between clopidogrel and proton pump inhibitors. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Plavix/32895609en.pdf. [Last accessed 26 March 2010]
   Google Scholar
• O'Donoghue ML, Braunwald E, Antman EM, Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989-97
   PubMed Web of Science ®Google Scholar
• Bhatt D, Cryer B, Contant C, The cogent trial. Available from: www.cardiosource.com/clinicaltrials/trial.asp?trialID=1872. [Last accessed 26 March 2010]
   Google Scholar
• Hart J, Hawkey CJ, Lanas A, Predictors of gastroduodenal erosions in patients taking low-dose aspirin. Aliment Pharmacol Ther 2010;31:143-9
   PubMed Web of Science ®Google Scholar
• Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-72
   PubMed Web of Science ®Google Scholar
• Konturek PC, Kania J, Hahn EG. Konturek JW. Ascorbic acid attenuates aspirin-induced gastric damage: role of inducible nitric oxide synthase. J Physiol Pharmacol 2006;57(Suppl 5):125-36
   PubMedGoogle Scholar
• Tseng CC, Wolfe MM. Nonsteroidal anti-inflammatory drugs. Med Clin North Am 2000;84:1329-44
   PubMed Web of Science ®Google Scholar
• Lamotte M, Annemans L, Evers T, Kubin M. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. Pharmacoeconomics 2006;24:155-69
   PubMed Web of Science ®Google Scholar
• Hsiao FY, Tsai YW, Huang WF, A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding. Clin Ther 2009;31:2038-47
   PubMed Web of Science ®Google Scholar
• Flossmann E, Rothwell PM.; British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007;369:1603-13
   PubMed Web of Science ®Google Scholar
• Baron JA, Cole BF, Sandler RS, A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9
   PubMed Web of Science ®Google Scholar
• Benamouzig R, Deyra J, Martin A, Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003;125:328-36
   PubMed Web of Science ®Google Scholar
• Logan RF, Grainge MJ, Shepherd VC, Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008;134:29-38
   PubMed Web of Science ®Google Scholar
• Sandler RS, Halabi S, Baron JA, A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90
   PubMed Web of Science ®Google Scholar
• Fortuny J, Johnson CC, Bohlke K, Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers. Clin Gastroenterol Hepatol 2007;5:1154-9
   PubMed Web of Science ®Google Scholar
• Sadeghi SC, Bain CJ, Pandeya N, Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev 2008;17:1169-78
   PubMed Web of Science ®Google Scholar
• Chan AT, Giovannucci EL, Meyerhardt JA, Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 2008;134:21-8
   PubMed Web of Science ®Google Scholar
• Graham DY, Chan FK. NSAIDs, risks, and gastroprotective strategies: current status and future. Gastroenterology 2008;134:1240-6
   PubMed Web of Science ®Google Scholar
• Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-58
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global cancer rates could increase by 50% to 15 million by 2020. Available from: http://www.who.int/mediacentre/news/releases/2003/pr27/en/. [Last accessed 14 June 2010]
   Google Scholar